GlassScriptPhysician profile
Christel Cuevas
NPI 1366735375
$4,338.24
in general payments reported to CMS, 2019-2025
32 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $431 · 2021: $583 · 2022: $933 · 2023: $822 · 2024: $639 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $840.25 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $539.36 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $401.12 | 2019-2024 | Xarelto |
| Medtronic, INC. | $324.32 | 2022-2024 | Turbohawk, In.Pact Admiral, Abre |
| Novartis Pharmaceuticals Corporation | $308.38 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $249.07 | 2022-2025 | Lifevest |
| Abiomed | $189.52 | 2021-2023 | Impella |
| Amgen INC. | $156.67 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $140.54 | 2020-2023 | Cardiomems |
| Ekos Corporation | $114.96 | 2019 | |
| Cvrx, INC. | $113.07 | 2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $109.04 | 2023-2024 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $105.23 | 2022-2025 | |
| Novo Nordisk INC | $90.93 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $81.21 | 2022-2025 | Camzyos, Eliquis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.46 | 2023-2025 | |
| Chiesi USA, INC. | $64.93 | 2021-2023 | Kengreal, Cleviprex |
| Angiodynamics, INC. | $62.46 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $57.95 | 2024 | |
| Acist Medical Systems, INC. | $49.89 | 2021-2022 | |
| Amarin Pharma, INC. | $37.24 | 2019-2020 | |
| Esperion Therapeutics, INC. | $34.35 | 2021-2023 | Nexletol |
| Medtronic Vascular, INC. | $29.10 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.29 | 2023 | Injectafer |
| Bard Peripheral Vascular, INC. | $22.39 | 2020 | |
| W. L. Gore & Associates, INC. | $22.10 | 2021 | |
| Daxor Corporation | $19.44 | 2024 | Bva-100 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.44 | 2024 | Jardiance |
| Shockwave Medical, INC | $15.68 | 2025 | |
| Arbor Pharmaceuticals, INC. | $15.17 | 2019 | |
| Acarix USA INC. | $14.84 | 2025 | Cadscor System |
| Kiniksa Pharmaceuticals International, Plc | $13.84 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christel Cuevas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.